Patents by Inventor Brent S. McKenzie

Brent S. McKenzie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS
    Publication number: 20130287775
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 31, 2013
    Inventors: Edward P. Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy L. Miller, Melanie A. Kleinschek, Kristian S. Bak-Jensen, Katia Boniface, Brent S. McKenzie, Rene de Waal Malefyt
  • Pathogenic TH17 Cells; related reagents and methods
    Publication number: 20120156699
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: February 24, 2012
    Publication date: June 21, 2012
    Applicant: Schering Corporation
    Inventors: Edward P. Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy Lynn Miller, Melanie A. Kleinschek, Katia Boniface, Kristian S. Bak-Jensen, Brent S. McKenzie, Rene de Waal Malefyt
  • COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS
    Publication number: 20100135998
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: February 26, 2008
    Publication date: June 3, 2010
    Inventors: Edward Paul Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy Lynn Miller, Melanie A. Kleinschek, Kristian S. Bak-Jensen, Katia Boniface, Brent S. McKenzie, Rene de Waal Malefyt